ArticleJournal of medicinal chemistry2020
Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.
Open access · hybridAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 49 citations in OpenAlex.
- RAD51-targeting small molecule degrader sensitizesActa pharmaceutica Sinica. B · 2026Article
- Review
- Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a Novel Phenyl Furan-Quinoline-Carboxylic Acid Series.ACS medicinal chemistry letters · 2026Article
- A Metabolites' Interplay Can Modulate DNA Repair by Homologous Recombination.International journal of molecular sciences · 2026Article
- Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer.Frontiers in oncology · 2026Review
- Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance.Clinical and translational medicine · 2026Review
- Targeting DNA repair mechanisms in cancer therapy: the role of small molecule DNA repair inhibitors.NAR cancer · 2025Review
- Computationally-designed aptamers targeting RAD51-BRCA2 interaction impair homologous recombination and induce synthetic lethality.Nature communications · 2025Article
- A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancer.Journal of experimental & clinical cancer research : CR · 2025Article
- Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity.Cell death discovery · 2025Article
- An interpretable artificial intelligence framework for designing synthetic lethality-based anti-cancer combination therapies.Journal of advanced research · 2024Article
- New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives.Journal of medicinal chemistry · 2024Review
- Antitumor Activity of the Xanthonoside XGAc in Triple-Negative Breast, Ovarian and Pancreatic Cancer by Inhibiting DNA Repair.Cancers · 2023Article
- Discovery of Ruthenium(II) Metallocompound and Olaparib Synergy for Cancer Combination Therapy.Journal of medicinal chemistry · 2023Article
- Synthesis and Anticancer Evaluation of New Indole-Based Tyrphostin Derivatives and Their (International journal of molecular sciences · 2023Article
- Identification of RAD51-BRCA2 Inhibitors UsingACS medicinal chemistry letters · 2022Article
- The Mechanistic Understanding of RAD51 Defibrillation: A Critical Step in BRCA2-Mediated DNA Repair by Homologous Recombination.International journal of molecular sciences · 2022Article
- Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes.Nature communications · 2022Article
- Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead.OncoTargets and therapy · 2022Review
- Recent Advances in the Development of Non-PIKKs Targeting Small Molecule Inhibitors of DNA Double-Strand Break Repair.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 1 country.
Greta BagnoliniComputational and Chemical Biology, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.
Domenico MilanoComputational and Chemical Biology, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.
Marcella ManerbaComputational and Chemical Biology, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.
Fabrizio SchipaniComputational and Chemical Biology, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.
Jose Antonio OrtegaComputational and Chemical Biology, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.
Dario GioiaComputational and Chemical Biology, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.
Federico FalchiComputational and Chemical Biology, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.
Andrea BalboniComputational and Chemical Biology, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.
Fulvia FarabegoliDepartment of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.
Francesca De FrancoTES Pharma S.r.l., Via Palmiro Togliatti 22bis, I-06073 Corciano, Perugia, Italy.
Janet RobertsonTES Pharma S.r.l., Via Palmiro Togliatti 22bis, I-06073 Corciano, Perugia, Italy.
Roberto PellicciariTES Pharma S.r.l., Via Palmiro Togliatti 22bis, I-06073 Corciano, Perugia, Italy.
Isabella PallaviciniDepartment of Experimental Oncology at the IEO, European Institute of Oncology IRCCS, IFOM-IEO Campus, Via Adamello 16, 20100 Milan, Italy.
Sebastiano PeriDepartment of Experimental Oncology at the IEO, European Institute of Oncology IRCCS, IFOM-IEO Campus, Via Adamello 16, 20100 Milan, Italy.
Saverio MinucciDepartment of Biosciences, University of Milan, Via Celoria 26, 20100 Milan, Italy.
Stefania GirottoComputational and Chemical Biology, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.
Giuseppina Di StefanoDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via S. Giacomo 14, 40126 Bologna, Italy.
Marinella RobertiDepartment of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.ORCID 0000-0001-9807-2886
Andrea CavalliComputational and Chemical Biology, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genoa, Italy.ORCID 0000-0002-6370-1176
Italian Institute of Technology · ITUniversity of Bologna · ITEuropean Institute of Oncology · ITUniversity of Milan · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with
Indexed as
AdenocarcinomaAntineoplastic AgentsBRCA2 ProteinCell Line, TumorDNA DamageDrug DiscoveryDrug SynergismHomologous RecombinationHumansModels, MolecularPancreatic NeoplasmsPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsProtein Interaction MapsRad51 RecombinaseAntineoplastic AgentsBRCA2 ProteinolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsRad51 RecombinaseSmall Molecule Libraries
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.